Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-20,000
Closed -$7.04M 701
2026
Q1
$7.04M Sell
20,000
-74,200
-79% -$26.5M 0.2% 144
2025
Q4
$30.8M Buy
94,200
+81,700
+654% +$25.9M 0.81% 24
2025
Q3
$3.53M Buy
+12,500
New +$3.63M 0.09% 233
2024
Q4
Sell
-40,500
Closed -$13M 448
2024
Q3
$13M Buy
40,500
+10,500
+35% +$3.43M 0.37% 85
2024
Q2
$9.37M Hold
30,000
0.27% 116
2024
Q1
$8.53M Buy
30,000
+12,500
+71% +$3.66M 0.27% 112
2023
Q4
$5.04M Buy
+17,500
New +$4.77M 0.2% 127

Other funds holding AMGN

J. Goldman & Co's AMGN Position: Q2 2026 in Review

J. Goldman & Co sold out of Amgen (AMGN) in Q2 2026, closing a stake of 9,900 shares — an estimated $3.48M sold.

J. Goldman & Co first reported a position in AMGN in Q2 2022 and held it in 10 quarters. The position peaked at $27.8M in Q3 2023. 3,150 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • J. Goldman & Co reported no remaining Amgen position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 9,900 Amgen shares in Q2 2026, an estimated $3.48M.
  • J. Goldman & Co first reported a position in Amgen in Q2 2022 and held it in 10 quarters.
  • J. Goldman & Co's Amgen position peaked at $27.8M in Q3 2023.
  • 3,150 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.